FI841128A - Pyrimidinderivat, deras framstaellning och deras anvaendning. - Google Patents

Pyrimidinderivat, deras framstaellning och deras anvaendning. Download PDF

Info

Publication number
FI841128A
FI841128A FI841128A FI841128A FI841128A FI 841128 A FI841128 A FI 841128A FI 841128 A FI841128 A FI 841128A FI 841128 A FI841128 A FI 841128A FI 841128 A FI841128 A FI 841128A
Authority
FI
Finland
Prior art keywords
deras
pyrimidinderivat
anvaendning
framstaellning och
och
Prior art date
Application number
FI841128A
Other languages
English (en)
Finnish (fi)
Other versions
FI841128A0 (fi
Inventor
Takao Takaya
Masayoshi Murata
Kiyotaka Ito
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838308290A external-priority patent/GB8308290D0/en
Priority claimed from GB838315542A external-priority patent/GB8315542D0/en
Priority claimed from GB838327859A external-priority patent/GB8327859D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of FI841128A0 publication Critical patent/FI841128A0/fi
Publication of FI841128A publication Critical patent/FI841128A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI841128A 1983-03-25 1984-03-21 Pyrimidinderivat, deras framstaellning och deras anvaendning. FI841128A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB838308290A GB8308290D0 (en) 1983-03-25 1983-03-25 Pyrimidinone derivatives
GB838315542A GB8315542D0 (en) 1983-06-07 1983-06-07 Pyrimidinone derivatives
GB838327859A GB8327859D0 (en) 1983-10-18 1983-10-18 Pyrimidine derivatives

Publications (2)

Publication Number Publication Date
FI841128A0 FI841128A0 (fi) 1984-03-21
FI841128A true FI841128A (fi) 1984-09-26

Family

ID=27262023

Family Applications (1)

Application Number Title Priority Date Filing Date
FI841128A FI841128A (fi) 1983-03-25 1984-03-21 Pyrimidinderivat, deras framstaellning och deras anvaendning.

Country Status (13)

Country Link
US (3) US4612376A (de)
EP (1) EP0123402B1 (de)
KR (1) KR840008333A (de)
CA (1) CA1256107A (de)
DE (1) DE3473875D1 (de)
DK (1) DK160492C (de)
ES (2) ES530916A0 (de)
FI (1) FI841128A (de)
GR (1) GR81758B (de)
HU (1) HU195195B (de)
NO (1) NO841168L (de)
PH (1) PH22022A (de)
SU (2) SU1349698A3 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US4598149A (en) * 1984-03-02 1986-07-01 Merck & Co., Inc. 3-amino-2-hydroxypropyl of pyrimidin-4-one useful as antihypertensive, cardioprotective, antiarrythmic, and antianginal agents
US4649142A (en) * 1984-06-25 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent
US4708958A (en) * 1986-09-24 1987-11-24 G. D. Searle & Co. 6-(imidazolyphenyl)-4-iminopyrimidinones useful as hypotensive agents
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
IT1270122B (it) * 1994-10-04 1997-04-28 Ist Superiore Sanita 6-benzil-4-ossopirimidine sostituite, processo per la loro preparazione e composizioni farmaceutiche che le contengono
US6244121B1 (en) * 1998-03-06 2001-06-12 Applied Materials, Inc. Sensor device for non-intrusive diagnosis of a semiconductor processing system
KR20110010824A (ko) 2003-01-14 2011-02-07 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료
JP4920410B2 (ja) 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
NZ565955A (en) 2005-08-22 2011-08-26 Melior Pharmaceuticals I Inc Methods and formulations for modulating lyn kinase activity and treating related disorders
NZ579227A (en) * 2007-02-20 2012-11-30 Melior Pharmaceuticals I Inc Methods of identifying activators of lyn kinase
BRPI0813167A2 (pt) * 2007-07-23 2014-12-23 Melior Discovery Inc Usos de uma composição e de um agente para modular a atividade e/ou a expressão de irs-1 e/ou akt, e, composto
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2011017296A1 (en) * 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
EP3378854B1 (de) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Verfahren zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen davon
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
WO2016031987A1 (ja) * 2014-08-29 2016-03-03 国立大学法人東京大学 オートタキシン阻害活性を有するピリミジノン誘導体
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018191166A1 (en) 2017-04-10 2018-10-18 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
CN109053589A (zh) * 2018-09-30 2018-12-21 浙江师范大学 4-亚胺基四氢嘧啶-2-酮类化合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296371A (de) * 1969-02-26 1972-11-15
AU1108070A (en) * 1969-03-06 1971-08-12 Imperial Chemical Industries Limited Pyrimidine derivatives
GB1336138A (en) * 1969-12-10 1973-11-07 Ici Ltd Process for the production of pyrimidine derivatives
US3923807A (en) * 1973-09-10 1975-12-02 Takeda Chemical Industries Ltd 6-Aminouracil derivatives
JPS5053381A (de) * 1973-09-20 1975-05-12
US4208366A (en) * 1978-10-31 1980-06-17 E. I. Du Pont De Nemours And Company Process for preparing a nonwoven web
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent

Also Published As

Publication number Publication date
ES8505972A1 (es) 1985-06-16
SU1349698A3 (ru) 1987-10-30
PH22022A (en) 1988-05-13
KR840008333A (ko) 1984-12-14
CA1256107A (en) 1989-06-20
DK160492C (da) 1991-08-26
US4824851A (en) 1989-04-25
US4612376A (en) 1986-09-16
ES8601922A1 (es) 1985-11-01
ES530916A0 (es) 1985-06-16
FI841128A0 (fi) 1984-03-21
SU1436872A3 (ru) 1988-11-07
US4746664A (en) 1988-05-24
DE3473875D1 (en) 1988-10-13
EP0123402A2 (de) 1984-10-31
DK160492B (da) 1991-03-18
EP0123402B1 (de) 1988-09-07
HU195195B (en) 1988-04-28
GR81758B (de) 1984-12-12
EP0123402A3 (en) 1985-09-18
DK166884D0 (da) 1984-03-23
NO841168L (no) 1984-09-26
ES538190A0 (es) 1985-11-01
DK166884A (da) 1984-09-26

Similar Documents

Publication Publication Date Title
FI843594L (fi) Trihalogenmetylgrupper innehaollande karbonylmetylenheterocykler, foerfarande foer deras framstaellning och ljuskaenslig blandning vilken innehaoller dessa foereningar.
FI845038L (fi) Vattenloeslig, aminerad -1,3-bunden d-glukan och komposition innehaollande densamma.
FI77939B (fi) Askorbatstoerningsfri komposition, anordning och foerfarande foer bestaemning av peroxidativt aktiva substanser.
FI843403A0 (fi) Blandarmatur foer blandning av tvao vaetskor, saerskilt kallt och varmt vatten.
FI843856A0 (fi) 1-benzyl-aminoalkyl-pyrrolidinoner och deras syraadditionssalter, foerfarande foer deras framstaellning och laekemedel.
FI841128A (fi) Pyrimidinderivat, deras framstaellning och deras anvaendning.
FI842459A0 (fi) Tetrahydropyridazinonderivat, foerfaranden foer deras framstaellning och deras anvaendning.
FI843342A0 (fi) Anordning foer traening av benmuskulatur, cirkulation och armmuskulatur.
FI841841A0 (fi) 1-pyrimidinyloxi-3-hetarylalkylamino-2- propanoler, deras framstaellning och anvaendning.
FI844889L (fi) Foernaetade polymerater, foerfarande foer deras framstaellning och deras anvaendning.
FI840206A (fi) Aminosyraderivat, foerfarande foer deras framstaellning och anvaendning.
FI830032L (fi) Foerfarande och anordning foer bestaemmande av en oenskad centrallinje foer cylinderlika kroppar, saosom traestockar.
FI840428A (fi) Biologiskt aktivt ketonderivat, framstaellning och anvaendning.
FI842210A (fi) Kefalosporinester-derivat, deras framstaellning och anvaendning.
FI841615A (fi) 4-fenyl-tetrahydro-furano-pyridiner, foerfarande foer deras framstaellning och farmaceutiska blandningar.
FI841479A (fi) Fenylalaninhydroxilas- cdna- kloner, foerfarande foer framstaellning av dessa och anvaendning av dessa foer diagnostisering av fenylketonuri.
FI842845A (fi) Foerfarande och anordning foer styrning av omkopplarna i en flerfasig pulsvaexelriktare, isynnerhet i en transistorvaexelriktare.
FI844002L (fi) Stabiliserade, inerta organiska vaetskor innehaollande natriumditionitprodukter och deras anvaendning.
FI843825L (fi) Faergkatodstraolroer, komponent och framstaellningsmetod.
FI840843A (fi) Plasmider, foerfarande foer framstaellning av dessa, mikroorganismer innehaollande dessa och foerfaranden foer odling av mikroorganismerna.
FI843824A0 (fi) Faergkatodstraolroer, komponent och framstaellningsmetod.
FI842300A0 (fi) Mono- och ditioestrar, deras framstaellning och anvaendning.
FI843973A0 (fi) Foerfarande foer oeverfoering, saerskilt foer registrering och aotergivning av faergtelevisionssignaler.
FI844884A0 (fi) Akryltelomerer innehaollande medelst ljus tvaerbindande sidokedjor, syntes daerav och anvaendning av dessa foer belaeggning av metaller.
FI840587A (fi) Mjoeldryga-alkaloider, deras framstaellning och anvaendning.

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: FUJISAWA PHARMACEUTICAL CO., LTD.